FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4251863399> ?p ?o ?g. }

• W4251863399 endingPage "1076" @default.
• W4251863399 startingPage "1071" @default.
• W4251863399 abstract "OBJECTIVE—The aim of this study was to assess the effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. RESEARCH DESIGN AND METHODS—This was a randomized, double-blind, controlled clinical trial. One hundred subjects (54 men and 46 women) with the metabolic syndrome, as defined by the Adult Treatment Panel III, were followed for 12 months after random assignment to rosiglitazone (4 mg/day) or placebo. Primary end points were flow-mediated dilation and high-sensitivity C-reactive protein (hs-CRP) levels; secondary end points were lipid and glucose parameters, homeostasis model assessment (HOMA) of insulin sensitivity, endothelial function score, and circulating levels of interleukin (IL)-6, IL-18, and adiponectin. RESULTS—Compared with 60 control subjects matched for age and sex, patients with the metabolic syndrome had decreased endothelial function, raised concentrations of inflammatory markers, and reduced insulin sensitivity. After 12 months, subjects with the metabolic syndrome receiving rosiglitazone showed improved flow-mediated vasodilation (4.2%, P &lt; 0.001) and reduced hs-CRP levels (−0.7 mg/dl, P = 0.04), compared with the placebo group. Moreover, HOMA (−0.8, P = 0.01) and serum concentrations of IL-6 (−0.5 pg/ml, P = 0.045) and IL-18 (−31 pg/ml, P = 0.036) were significantly reduced in subjects receiving rosiglitazone, whereas adiponectin levels showed a significant increment (2.3 μg/ml, P = 0.02). High-density lipoprotein-cholesterol levels increased more and triglyceride levels decreased more in the rosiglitazone group compared with the placebo group. At 1 year of follow-up, 30 subjects receiving rosiglitazone still had features of the metabolic syndrome, compared with 45 subjects receiving placebo (P &lt; 0.001). CONCLUSIONS—Rosiglitazone might be effective in reducing the prevalence of the metabolic syndrome." @default.
• W4251863399 created "2022-05-12" @default.
• W4251863399 creator A5003789168 @default.
• W4251863399 creator A5005106875 @default.
• W4251863399 creator A5028710096 @default.
• W4251863399 creator A5037546600 @default.
• W4251863399 creator A5044764461 @default.
• W4251863399 creator A5052044111 @default.
• W4251863399 creator A5055583365 @default.
• W4251863399 creator A5056173815 @default.
• W4251863399 creator A5069148336 @default.
• W4251863399 creator A5080011175 @default.
• W4251863399 creator A5081455032 @default.
• W4251863399 date "2006-05-01" @default.
• W4251863399 modified "2023-10-04" @default.
• W4251863399 title "Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome" @default.
• W4251863399 cites W121348928 @default.
• W4251863399 cites W1585890476 @default.
• W4251863399 cites W1608005125 @default.
• W4251863399 cites W1639924204 @default.
• W4251863399 cites W1968243232 @default.
• W4251863399 cites W1977662423 @default.
• W4251863399 cites W1985882893 @default.
• W4251863399 cites W1989619519 @default.
• W4251863399 cites W1997030483 @default.
• W4251863399 cites W1999775886 @default.
• W4251863399 cites W2008839943 @default.
• W4251863399 cites W2014663082 @default.
• W4251863399 cites W2018135697 @default.
• W4251863399 cites W2018176172 @default.
• W4251863399 cites W2023731005 @default.
• W4251863399 cites W2052013968 @default.
• W4251863399 cites W2058610272 @default.
• W4251863399 cites W2058699849 @default.
• W4251863399 cites W2060449981 @default.
• W4251863399 cites W2065827854 @default.
• W4251863399 cites W2086040049 @default.
• W4251863399 cites W2088981742 @default.
• W4251863399 cites W2092881968 @default.
• W4251863399 cites W2094394439 @default.
• W4251863399 cites W2095726149 @default.
• W4251863399 cites W2098065069 @default.
• W4251863399 cites W2102469433 @default.
• W4251863399 cites W2111184067 @default.
• W4251863399 cites W2121982383 @default.
• W4251863399 cites W2123289485 @default.
• W4251863399 cites W2142179136 @default.
• W4251863399 cites W2146763966 @default.
• W4251863399 cites W2160234571 @default.
• W4251863399 cites W2164367541 @default.
• W4251863399 cites W2311395955 @default.
• W4251863399 cites W2469307620 @default.
• W4251863399 cites W4238251256 @default.
• W4251863399 cites W4240449862 @default.
• W4251863399 doi "https://doi.org/10.2337/dc05-2174" @default.
• W4251863399 hasPublicationYear "2006" @default.
• W4251863399 type Work @default.
• W4251863399 citedByCount "90" @default.
• W4251863399 countsByYear W42518633992012 @default.
• W4251863399 countsByYear W42518633992013 @default.
• W4251863399 countsByYear W42518633992015 @default.
• W4251863399 countsByYear W42518633992016 @default.
• W4251863399 countsByYear W42518633992017 @default.
• W4251863399 countsByYear W42518633992018 @default.
• W4251863399 countsByYear W42518633992019 @default.
• W4251863399 countsByYear W42518633992020 @default.
• W4251863399 countsByYear W42518633992021 @default.
• W4251863399 countsByYear W42518633992022 @default.
• W4251863399 countsByYear W42518633992023 @default.
• W4251863399 crossrefType "journal-article" @default.
• W4251863399 hasAuthorship W4251863399A5003789168 @default.
• W4251863399 hasAuthorship W4251863399A5005106875 @default.
• W4251863399 hasAuthorship W4251863399A5028710096 @default.
• W4251863399 hasAuthorship W4251863399A5037546600 @default.
• W4251863399 hasAuthorship W4251863399A5044764461 @default.
• W4251863399 hasAuthorship W4251863399A5052044111 @default.
• W4251863399 hasAuthorship W4251863399A5055583365 @default.
• W4251863399 hasAuthorship W4251863399A5056173815 @default.
• W4251863399 hasAuthorship W4251863399A5069148336 @default.
• W4251863399 hasAuthorship W4251863399A5080011175 @default.
• W4251863399 hasAuthorship W4251863399A5081455032 @default.
• W4251863399 hasBestOaLocation W42518633991 @default.
• W4251863399 hasConcept C126322002 @default.
• W4251863399 hasConcept C134018914 @default.
• W4251863399 hasConcept C142724271 @default.
• W4251863399 hasConcept C204787440 @default.
• W4251863399 hasConcept C27081682 @default.
• W4251863399 hasConcept C2776782570 @default.
• W4251863399 hasConcept C2776914184 @default.
• W4251863399 hasConcept C2777391703 @default.
• W4251863399 hasConcept C2778163477 @default.
• W4251863399 hasConcept C2778270857 @default.
• W4251863399 hasConcept C2778901321 @default.
• W4251863399 hasConcept C2778913445 @default.
• W4251863399 hasConcept C2779306644 @default.
• W4251863399 hasConcept C2780152017 @default.
• W4251863399 hasConcept C2780578515 @default.
• W4251863399 hasConcept C2780972559 @default.

• next